吉利德科学在其最新报告中展望了2026财年的前景。公司预计，在不考虑政策变动带来的不利因素下，其核心业务板块——艾滋病（HIV）治疗药物的销售额将实现稳健增长，预计2026财年将比2025财年提升约8%。这一增长预期凸显了公司在抗病毒领域的持续市场优势和发展潜力。
吉利德科学在其最新报告中展望了2026财年的前景。公司预计，在不考虑政策变动带来的不利因素下，其核心业务板块——艾滋病（HIV）治疗药物的销售额将实现稳健增长，预计2026财年将比2025财年提升约8%。这一增长预期凸显了公司在抗病毒领域的持续市场优势和发展潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.